Recent News

• 03.31.2026 - VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
• 03.31.2026 - VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
• 03.30.2026 - Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
• 03.26.2026 - Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
• 03.25.2026 - VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
• 03.25.2026 - Volition Announces Detection of Over 95% of Early-Stage Cancers
• 03.18.2026 - Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
• 03.06.2026 - Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Recent Filings

• 03.31.2026 - EX-99.1 EX-99.1
• 03.31.2026 - 8-K Current report
• 03.31.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities